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Abstract 
 
Exercise triggers a pleiotropic response in skeletal muscle, which results in a 
profound remodeling of this tissue. Physical activity-dependent muscle fiber plasticity 
is regulated by a number of distinct signaling pathways. Even though most of these 
pathways are activated by different stimuli and in a temporally and spatially separated 
manner during exercise, many of the major signal transduction events converge on the 
peroxisome proliferator-activated receptor  coactivator 1 (PGC-1) by 
posttranslationally modifying the PGC-1 protein, modulating PGC-1 gene 
expression or both. In turn, depending on the cellular context, PGC-1 regulates 
specific gene programs. Ultimately, PGC-1 modulates many of the transcriptional 
adaptations of skeletal muscle to exercise. In this review, the regulation and function 
of this pivotal transcriptional coactivator in muscle are discussed. 
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Background 
 
Skeletal muscle is an extremely versatile tissue that can respond to a variety of 
external stimuli, including changes in the levels of physical activity, temperature, 
oxygen, nutrient supply and composition (1-3). Plasticity of this organ is facilitated by 
different muscle fiber types within muscle beds. Oxidative, fatigue resistant type I and 
type IIa muscle fibers enable high endurance activities whereas glycolytic, fast twitch 
type IIx and type IIb fibers allow explosive movements with maximal peak force 
generation (4, 5). Before, during and after exercise bouts, neuronal, hormonal, 
mechanical and metabolic parameters affect contracting muscle fibers and trigger 
appropriate adaptations for subsequent muscle loading events. An inability of muscle 
to properly function or respond to external stimuli has drastic health consequences, as 
observed in many muscular dystrophies. Similarly, a voluntary or forced relative 
physical inactivity is a severe and independent risk factor for many chronic diseases, 
thereby compromising quality of life and reducing life expectancy (2, 3, 6-8). 
 
Despite the obvious consequences of physical activity on human health, surprisingly 
little is known about the molecular mechanisms that regulate skeletal muscle 
plasticity in the active and inactive muscle fiber, respectively. While individual 
signaling pathways have been identified, the coordination of the complex response, 
that even in a single bout of endurance exercise comprises a change in the expression 
of more than 900 genes (9), remains enigmatic. In recent years, the increasing use of 
molecular biology and transgenic techniques revealed candidate factors that 
contribute to the exercise response in muscle. In particular, the peroxisome 
proliferator-activated receptor  coactivator 1 (PGC-1), a transcriptional 
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coactivator protein, emerged as a central regulator in exercise-induced muscle fiber 
plasticity (6, 7, 10-12). 
 
PGC-1: a master regulator of mitochondrial biogenesis and function 
 
Similar to the different fiber types in muscle, fat also consists of two tissue subtypes 
that vary dramatically in their oxidative capacity, brown and white adipose tissue, 
respectively (13). Pere Puigserver, Zhidan Wu, Bruce Spiegelman and colleagues 
used these two types of fat to search for factors that determine an oxidative phenotype 
and thereby established PGC-1 as a master regulator of mitochondrial biogenesis 
and activity (14, 15). According to this core function, PGC-1 is expressed in every 
oxidative tissue with a high energy turnover, including brain, heart, muscle, liver, 
kidney, brown adipose tissue, and pancreas (6, 10, 11, 16). Importantly, in addition to 
promote mitochondrial function and oxidative metabolism, PGC-1 regulates many 
tissue-specific processes, such as fasting-induced hepatic gluconeogenesis, glucose-
stimulated pancreatic insulin secretion and cold-mediated adaptive thermogenesis in 
brown adipose tissue. 
 
PGC-1 is a transcriptional coactivator and therefore relies on interactions with 
DNA-binding transcription factors in order to be recruited to target gene promoters 
(16, 17). Such interactions are formed with various members of the nuclear receptor 
superfamily, but also many non-nuclear receptor-type transcription factors. The 
functional domains that mediate the binding of PGC-1 to transcription factors are 
located throughout the PGC-1 protein: nuclear receptors predominantly bind to 
LXXLL and LLXXL domains at the N-terminus whereas other factors such as FoxO1 
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or the myocyte enhancer factors 2 (MEF2) interact more C-terminally (16, 17). Once 
bound to a transcription factor, PGC-1 serves as a protein docking platform and 
assembles histone acetyl-transferase (HAT), TRAP/DRIP/Mediator and SWI/SNF 
complexes (18-20). As a consequence, transcription of PGC-1 target genes is greatly 
increased. 
 
The PGC-1 protein can vary depending on alternative splicing of its transcript (21), 
usage of two different promoters separated by 13kb in the mouse genome (22), and 
posttranslational modifications. So far, phosphorylation by the AMP-dependent 
protein kinase (AMPK) (23), p38 mitogen-activated protein kinase (p38 MAPK) (24, 
25) and protein kinase B (PKB/Akt) (26) at different serine and threonine residues, 
lysine acetylation and deacetylation by GCN5 and SIRT1, respectively (27, 28), 
arginine methylation by PRMT1 (29), ubiquitination (30), lysine sumoylation (31) 
and serine O-linked -N-acetylglucosamination (32) have been described to alter the 
stability, activity or specificity of the PGC-1 protein or modulate the interaction with 
binding partners such as the repressor p160 myb (33). Combinatorially, these 
differences in splicing, promoter usage and protein modifications enable a huge 
repertoire of PGC-1 protein species and thereby provide the base for an extremely 
fine-tuned and specific regulation of PGC-1 level and function (10). Together with 
the ability to bind to many different transcription factors, this variability of the PGC-
1 protein confers significant advantages to this transcriptional coactivator over any 
individual transcription factors to regulate complex biological programs (34-36). In a 
similar fashion, transcriptional regulators form large protein complexes, sometimes 
even including RNA-based coregulators, to control the expression of gene families in 
other tissues (37). Some of these coregulators, for example the nuclear receptor 
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coregulator (NRC), are multifunctional and involved in the regulation of many 
different cellular processes (38). 
 
Expression and regulation of PGC-1 in skeletal muscle 
 
In skeletal muscle, PGC-1 exhibits a fiber type-specific expression pattern with 
higher levels in oxidative type I and IIa compared to glycolytic type IIx and IIb fibers 
(39). Analogous to the metabolic and external stimuli that induce PGC-1 in other 
tissues, such as fasting in the liver or cold in brown adipose tissue, physical activity is 
the major driver that alters PGC-1 gene expression in muscle (21). PGC-1 is 
acutely induced during an endurance exercise bout, and the levels revert to those 
observed pre-exercise within a couple of hours (40). Concomitant with a fiber type 
shift towards oxidative fibers, chronic endurance exercise increases the basal 
expression of PGC-1 while retaining the pulsatile regulation during each individual 
exercise bout (40, 41). In contrast, muscular inactivity results in a rapid decline in 
PGC-1 levels (42). 
 
Motor neuron-induced muscle fiber contractions are mediated by a transient rise in 
intramyocellular calcium (43). Calcium signaling is also involved in increasing the 
transcription of PGC-1 via activation of the calcium/calmodulin-dependent protein 
kinase (CaMK) and the protein phosphatase calcineurin A (CnA) (44, 45). 
Subsequently, the altered phosphorylation status of MEF2C/D and the cyclic AMP-
responsive element binding protein (CREB) result in an activation of these 
transcription factors, binding to the PGC-1 promoter and induction of PGC-1 
transcription (45, 46). Interestingly, the PGC-1 protein competes with histone 
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deacetylases (HDAC) for binding to MEF2C/D and thereby controls its own 
transcription in a positive autoregulatory loop (45, 47). 
 
In addition to the regulation of PGC-1 gene expression by motor neuron activity, 
many of the other major signaling pathways that are induced in a contracting muscle 
fiber also converge on this coactivator by either activating PGC-1 transcription, 
modifying the PGC-1 protein, or both (Fig. 1). Even preceding transcriptional 
induction of the PGC-1 gene, the mechanical stress of fiber contraction activates the 
p38 MAPK, which then phosphorylates and stabilizes the PGC-1 protein (24, 48). 
Contractile stress-mediated generation of reactive oxygen species (ROS) triggers an 
adaptive response by inducing PGC-1 gene expression and subsequently elevating 
ROS detoxifying enzyme levels (49). The metabolic demand of exercise results in a 
shift of the ratio of AMP to ATP and of NAD+ to NADH. AMPK is an important 
energy sensor in muscle, which promotes metabolic pathways that favor ATP 
synthesis (50). Once activated by rising AMP levels, AMPK phosphorylates the PGC-
1 protein and induces PGC-1 gene expression (23). PGC-1 in turn regulates 
some, but not all of the AMPK target genes (23). Similarly, augmented NAD+ 
activates the protein deacetylase SIRT1, which deacetylates and activates PGC-1 
(51, 52). The increased muscle tone during exercise results in vascular occlusion in 
this tissue. In combination with increased oxygen consumption, hypoxic conditions 
occur as a consequence in working muscle (53). Subsequent compensatory 
mechanisms trigger exercise hyperemia that in turn leads to microvascular shear stress 
(54). Both the hypoxic signaling and the endothelial released nitric oxide boost PGC-
1 transcription (55, 56). The hormonal milieu peri- and post-exercise is 
characterized by fight-or-flight signals and anti-inflammatory stimuli in the repair 
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phase, respectively. Activators of 2-adrenergic receptors, thyroid hormone and 
corticosteroids all induce PGC-1 gene expression in muscle fibers (57-59). Finally, 
in the vicinity of the neuromuscular junction, paracrine factors released from the 
motor neuron such as the neurotrophic factor neuregulin promote phosphorylation of 
the PGC-1 protein (60). 
 
At the moment, it is unclear how the effects of these different signaling pathways on 
PGC-1 are integrated. However, it is evident that a temporal and spatial coordination 
exist. As mentioned, rapid stabilization of the PGC-1 protein by p38 MAPK 
phosphorylation precedes transcriptional induction of the gene (48), ultimately 
followed by ubiquitination and degradation of the protein (30). Furthermore, all the 
signaling pathways in the contracting muscle fiber that converge on PGC-1 are 
activated in specific cellular contexts. Accordingly, PGC-1 function is controlled by 
posttranslational modifications to react to these defined situations (Fig. 2). For 
example, only PGC-1 protein in subsynaptic nuclei will be modified by neurotrophic 
factor signaling (60). Thereby, induction of gene expression of post-synaptic 
neuromuscular junction genes in these nuclei is achieved, but not in other, non-
subsynaptic nuclei where expression of these genes is not required. Activation of 
AMPK and SIRT1 reflects an energy crisis of the muscle fiber. The posttranslational 
modifications of PGC-1 by this protein kinase and deacetylase, respectively, 
primarily increase the expression of PGC-1 target genes that are involved in 
substrate oxidation and ATP synthesis (23, 51). In contrast, many of the other PGC-
1-controlled gene families are not regulated in this context and thereby, further 
breakdown of ATP is avoided. 
 
 - 10 - 
PGC-1 regulates many of the adaptations of skeletal muscle to endurance 
exercise 
 
Moderate ectopic expression of PGC-1 in skeletal muscle that mimics the increase 
in PGC-1 levels after chronic exercise induces pleiotropic changes in muscle fibers 
(39, 61). Most importantly, muscle-specific PGC-1 transgenic mice have muscle 
fibers with an increased fatigue resistance and exhibit an improved endurance 
exercise performance (39, 62). Whether PGC-1 indeed controls the complete 
exercise-regulated muscle cell plasticity remains to be shown. However, ectopic 
elevation of PGC-1 in muscle is sufficient to trigger all of the adaptations of skeletal 
muscle that are important for increased endurance (Fig. 3). Glucose uptake and 
glycogen synthesis are increased by PGC-1 in muscle whereas glycolysis is 
inhibited (61, 63). In endurance trained muscle, lipids are the preferred substrate for 
ATP synthesis. Accordingly, PGC-1 strongly induces mitochondrial biogenesis and 
function in muscle by promoting gene expression of nuclear-encoded mitochondrial 
genes, the mitochondrial transcription factor A that is required for replication of 
mitochondrial DNA (15, 39, 64-68) and of mitofusin 2, a protein involved in 
mitochondrial fission and fusion that regulates morphology and distribution of 
mitochondria (69). In particular, mitochondrial fatty acid  oxidation, the Krebs cycle 
and oxidative phosphorylation are augmented by PGC-1 (61, 70-72). Interestingly, 
PGC-1 boosts both total as well as uncoupled mitochondrial respiration, most likely 
by inducing the expression of the uncoupling protein 2 (UCP-2) in muscle (49, 64). 
Mitochondrial uncoupling might be part of the broader, PGC-1-regulated 
detoxification system against reactive oxygen species (ROS) that are generated in 
contracting muscle fibers (49, 73). Many of the mitochondrial proteins that are 
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elevated by PGC-1 contain heme as the prosthetic group (74). To meet the increased 
demand for heme, PGC-1 induces the expression of the first and rate-limiting 
enzyme of heme biosynthesis, the housekeeping -aminolevulinate synthase 1 
(ALAS-1) (66, 75). Adequate oxygen levels for the oxidative metabolism are 
provided by PGC-1-controlled angiogenesis and increase in myoglobin levels (39, 
55, 76). As a consequence of these adaptations, a steady supply of ATP is generated 
that can be used by myofibrillar proteins that are prototypical of oxidative muscle 
fibers, including troponin I slow and the myosin heavy chains I and IIa, which also 
are directly regulated by PGC-1 (39, 65). PGC-1-driven gene expression of 
postsynaptic neuromuscular junction genes provides a feedback for the tonic motor 
neuron input in endurance exercise by remodeling the neuromuscular junction (60). In 
addition, inhibition of FoxO3 by PGC-1 reduces the expression of ubiquitine ligases 
that mediate protein degradation and fiber atrophy in inactive fibers (42). Moreover, 
muscle cell apoptosis and autophagy are reduced by PGC-1 (77). Finally, muscle 
performance differs with the time of the day, usually being higher in the afternoon 
than in the morning (78). Accordingly, PGC-1 expression in muscle exhibits 
circadian variations (79). However, circadian peak muscle performance can be 
entrained by repeated muscle activity because muscle contraction is one of the major 
time cues, or zeitgeber, for the peripheral circadian clock in skeletal muscle (78). 
PGC-1 coactivates the retinoic acid receptor-related orphan nuclear receptors  and 
 (ROR and ROR) and thereby regulates the expression of clock genes that control 
the circadian rhythm in muscle (79). Therefore, PGC-1 might link physical activity 
to muscle-cell autonomous clock function in exercise-mediated entrainment of the 
circadian rhythm. 
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Pathological consequences of PGC-1 dysregulation in muscle and therapeutic 
potential 
 
Reduced levels of PGC-1 in skeletal muscle have been reported in different disease 
contexts, including type 2 diabetic patients, aging and pathologically inactive muscle 
(42, 80-82). In human patients, it is unclear whether the decrease in PGC-1 levels in 
muscle is cause or consequence of these pathologies. However, animal models with a 
muscle-specific knockout of one or both PGC-1 alleles offer important insights into 
the health consequences of reduced PGC-1. In many ways, muscle-specific PGC-1 
knockout mice are a phenotypical mirror image of muscle-specific PGC-1 
transgenic animals. Mitochondrial biogenesis and function are reduced in PGC-1 
muscle knockouts and the proportion of glycolytic relative to oxidative fibers is 
increased (65, 66). Moreover, these mice exhibit reduced voluntary physical activity 
as well as a dramatically impaired endurance capacity when exercised (65). 
Surprisingly, muscle fiber damage and serum creatine kinase are increased in muscle-
specific PGC-1 knockout animals (65). This fiber damage is further exacerbated by 
physical activity indicating a role for PGC-1 in the maintenance of muscle fiber 
integrity (65). Furthermore, the expression of several pro-inflammatory genes is 
augmented in these animals (66). Interestingly, increased circulating levels of the pro-
inflammatory cytokines interleukin 6 (IL-6) and, at least after exercise, of the tumor 
necrosis factor  (TNF) are found in muscle-specific PGC-1 knockouts (66). 
Related to this change in circulating factors, a muscle-specific ablation of the PGC-1 
gene results in systemic changes that affect distal organs, for example pancreatic islets 
that exhibit an abnormal morphology and impaired insulin secretion in vivo (66). 
Thus, like a sedentary life style that is associated with an increased risk for many 
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chronic diseases and a reduced life expectancy, PGC-1 dysregulation in muscle 
elicits profound systemic effects and could be the molecular event that links 
inactivity, inflammation and chronic diseases (7, 8). 
 
Inversely, therapeutic elevation of PGC-1 in muscle has the potential to ameliorate 
many different diseases (6). In animal models, a high efficacy of ectopically 
expressed PGC-1 in muscle has been shown in muscle wasting diseases. For 
example, fiber damage, serological markers of muscle wasting and exercise 
intolerance of a mouse model for Duchenne muscular dystrophy are significantly 
reduced by increased PGC-1 in muscle (60). Similarly, in a mouse line with ablation 
of the Cox10 gene that recapitulates the pathologies of a mitochondrial myopathy, life 
expectancy is increased by several months concomitant with an amelioration of ATP 
generation and exercise capacity when crossed with muscle-specific PGC-1 
transgenic animals (83). In a severe model of fiber atrophy, mice with denervated 
hind legs, ectopic expression of PGC-1 almost completely prevents the normally 
occurring muscle fiber atrophy (42). Thus, even in the absence of a functional motor 
neuron, preventing the drop of PGC-1 that accompanies muscle inactivity is 
sufficient to retain an active muscle phenotype. Furthermore, muscle morphology 
disruption by drugs of the statin class can be prevented by PGC-1 in a zebrafish 
model (84). Finally, muscle-specific PGC-1 transgenic mice are resistant against 
age-associated muscle wasting, so-called sarcopenia (77). Importantly, regardless of 
the pathological context, increased PGC-1 expression rectifies muscle wasting, fiber 
damage and atrophy in these diseases with completely different etiologies. It is thus 
conceivable that the ability of PGC-1 to induce an endurance trained-like phenotype 
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enables a broad therapeutic spectrum of PGC-1-based interventions against many 
muscle diseases (6, 7). 
 
Finally, exercise reduces the risk for developing many chronic diseases by affecting 
almost every organ in the body (3). Similarly, modulation of PGC-1 in skeletal 
muscle has systemic consequences: loss-of-function is associated with increased 
inflammation (65, 66), gain-of-function in mice improves many parameters of aging 
and most importantly, significantly extends the life span of muscle-specific PGC-1 
transgenic mice (77). Therefore, therapeutic modulation of PGC-1 in muscle might 
extend beyond isolated effects on this tissue and, like exercise, improve health, life 
quality and life expectancy in general. 
 
Conclusion and outlook 
 
In recent years, tremendous progress has been made in understanding the molecular 
mechanisms that regulate skeletal muscle cell plasticity in health and disease. Of 
particular interest is the discovery of the transcriptional coactivator PGC-1 as a key 
factor in the adaptation of muscle to endurance exercise. Despite these breakthroughs, 
many unknowns in this complex biological program still exist. For example, the 
coordination and integration of the numerous signaling pathways in a contracting 
muscle fiber that converge on PGC-1 remain enigmatic. Likewise, the cellular 
functions that are triggered by PGC-1 and that mediate the therapeutically beneficial 
effects of augmented levels of this coactivator on different muscle pathologies are 
mysterious. Furthermore, the distinct roles and functional overlap between the three 
members of the PGC-1 family, PGC-1, PGC-1 and the PGC-1-related coactivator 
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PRC, have not been studied in muscle. Then, despite screening efforts, safe 
pharmacological interventions that chronically induce PGC-1 within a 
therapeutically desired window specifically in skeletal muscle are unknown (59, 85). 
Such drugs are essential to avoid detrimental effects of excessive PGC-1 in muscle 
or other tissues (6, 39, 86, 87) and of unwanted side effects of PGC-1 induction in 
distal organs, for example elevation of hepatic gluconeogenesis (6, 88). Finally, while 
ectopic expression of PGC-1 in muscle is sufficient to induce a trained phenotype 
(39), it is currently unclear whether PGC-1 is also necessary for training adaptation 
of muscle. Global PGC-1 knockout animals exhibit an almost normal training 
response to endurance exercise in young mice (89) but an impaired training-induced 
prevention of a decline in mitochondrial function in aging (90), despite or maybe 
because of their complex and confounding phenotype (67). However, the phenotype 
of these global PGC-1 knockout mice can be diametrically opposite to that of tissue-
specific PGC-1 knockout mice. For example, hepatic gluconeogenesis is 
constitutively elevated in global PGC-1 knockout mice (67) whereas liver-specific 
PGC-1 knockout animals exhibit reduced fasting-induced glucose production in the 
liver (75), as expected from previous gain-of-function studies (91). In muscle, an 
unaltered fiber type distribution and activated AMPK were observed in global PGC-
1 knockout animals (92) in contrast to the fiber type switch towards glycolytic fibers 
and normal AMPK activity in muscle-specific PGC-1 knockout mice (65, 66). 
Indeed, preliminary exercise studies with muscle-specific PGC-1 knockout animals 
indicate that this coactivator is indispensable for at least some of the endurance 
training adaptations, including muscle tissue vascularization and mitochondrial 
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biogenesis (76, 93). However, more comprehensive experiments are needed to further 
address this controversy. 
 
The surprising finding that a coactivator, not a transcription factor, seems to be the 
nexus of muscle adaptation to exercise indicates that exciting years are yet to come 
for the study of muscle cell plasticity. Although many big gaps in our basic 
understanding of the molecular events up- and downstream of PGC-1 have to be 
filled, experiments with PGC-1 in different disease models are promising for the 
development of novel therapeutic avenues to treat muscular dystrophies, muscle 
wasting, and maybe even diseases that are associated with other organs. However, 
while the search for pharmaceutical entities for the modulation of PGC-1 in muscle 
goes on, exercise and a balanced diet remain the best interventions to ensure a long 
and healthy life. 
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Figure Legends 
 
Fig. 1. Major exercise-induced signaling pathways converge on PGC-1 in 
skeletal muscle. The neuronal input, hormonal milieu, fiber contraction, mechanical 
stress and metabolic demand result in the activation of various signal transduction 
pathways. As a consequence, these signals lead to posttranslational modifications of 
the PGC-1 protein, alterations of PGC-1 gene expression, or both. 
 
Fig. 2. Posttranslational modifications of the PGC-1 protein specify the 
transcriptional response. Many signal transduction pathways result in 
posttranslational modifications of PGC-1. As a result of some of these 
modifications, the expression of specific PGC-1 target genes is modulated. For 
examples, neurotrophic signaling leads to transcriptional induction of neuromuscular 
junction genes by PGC-1 in nuclei close to the neuron-muscle interface. 
Phosphorylation of PGC-1 by the AMP-dependent protein kinase (AMPK) primarily 
affects PGC-1 target genes that are used to generate ATP and thereby rectify the 
energy crisis. In contrast, general elevation of PGC-1 in muscle results in the 
transcriptional regulation of a number of different gene families. 
 
Fig. 3. PGC-1 regulates a pleiotropic response to exercise in skeletal muscle. 
Known effects of PGC-1 in skeletal muscle and putative transcription factor binding 
partners involved in these functions are listed. Abbreviations: ERR, estrogen-related 
receptor ; GABP/NRF2, GA-binding protein/nuclear respiratory factor 2; FoxO1/3, 
forkhead box O1/3; MEF2, myocyte enhancer factor 2; NRF1, nuclear respiratory 
 - 31 - 
factor 1; OXPHOX, oxidative phosphorylation; PPAR, peroxisome proliferator-
activated receptor ; ROR/, retinoic acid receptor-related orphan receptor /; 
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